Drew, Yvette

Homologous recombination deficiency and ovarian cancer

Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 258

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Drew, Y., de Jonge, M., Hong, S. H., Park, Y. H., Wolfer, A., Brown, J., Ferguson, M., Gore, M. E., Alvarez, R. H., Gresty, C., et al. (2018) · Gynecologic Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 131

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

Smith, H. L., Willmore, E., Mukhopadhyay, A., Drew, Y., & Curtin, N. J. (2022) · Cancers

PARP inhibition in cancer therapyChronic Lymphocytic Leukemia Research

Cited by 9